Compare LRN & VCYT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LRN | VCYT |
|---|---|---|
| Founded | 2000 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Medical Specialities |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 2.8B |
| IPO Year | 2007 | 2013 |
| Metric | LRN | VCYT |
|---|---|---|
| Price | $85.92 | $36.46 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $106.75 | $46.50 |
| AVG Volume (30 Days) | ★ 938.5K | 798.2K |
| Earning Date | 04-28-2026 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 26.87 | ★ 164.52 |
| EPS | ★ 3.49 | 0.82 |
| Revenue | ★ $917,734,000.00 | N/A |
| Revenue This Year | $6.06 | $11.95 |
| Revenue Next Year | $5.10 | $11.97 |
| P/E Ratio | ★ $24.82 | $43.33 |
| Revenue Growth | ★ 3.29 | N/A |
| 52 Week Low | $60.61 | $22.61 |
| 52 Week High | $171.17 | $50.71 |
| Indicator | LRN | VCYT |
|---|---|---|
| Relative Strength Index (RSI) | 62.67 | 46.16 |
| Support Level | $62.76 | $34.60 |
| Resistance Level | $91.60 | $37.24 |
| Average True Range (ATR) | 3.06 | 1.49 |
| MACD | -0.29 | 0.22 |
| Stochastic Oscillator | 83.99 | 38.35 |
Stride Inc is an American online educational company. It offers alternative programs to traditional on-campus schooling. It also operates state-funded virtual charter schools around the United States. The educational programs for K-12 students are usually monitored by parents and provide virtual classroom environments where teachers meet with students online, by phone, or in-person. The company's contractual agreements with various school districts to offer its curriculum programs provide a majority of the company's revenue. The company lines of business are Managed Public School Programs, Institutional and Private Pay Schools and Other.
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.